- Home
- CEV vs NRXP Comparison
CEV vs NRXP Comparison
Compare CEV & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- NRXP
- Stock Information
- Founded
- CEV 1999
- NRXP 2015
- Country
- CEV United States
- NRXP United States
- Employees
- CEV N/A
- NRXP N/A
- Industry
- CEV Finance/Investors Services
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- NRXP Health Care
- Exchange
- CEV Nasdaq
- NRXP Nasdaq
- Market Cap
- CEV 67.8M
- NRXP 58.5M
- IPO Year
- CEV N/A
- NRXP N/A
- Fundamental
- Price
- CEV $9.47
- NRXP $2.64
- Analyst Decision
- CEV
- NRXP Strong Buy
- Analyst Count
- CEV 0
- NRXP 4
- Target Price
- CEV N/A
- NRXP $29.25
- AVG Volume (30 Days)
- CEV 19.6K
- NRXP 382.1K
- Earning Date
- CEV 01-01-0001
- NRXP 08-18-2025
- Dividend Yield
- CEV 4.23%
- NRXP N/A
- EPS Growth
- CEV N/A
- NRXP N/A
- EPS
- CEV 0.36
- NRXP N/A
- Revenue
- CEV N/A
- NRXP N/A
- Revenue This Year
- CEV N/A
- NRXP N/A
- Revenue Next Year
- CEV N/A
- NRXP $231.16
- P/E Ratio
- CEV $29.36
- NRXP N/A
- Revenue Growth
- CEV N/A
- NRXP N/A
- 52 Week Low
- CEV $8.83
- NRXP $1.10
- 52 Week High
- CEV $10.91
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- CEV 45.58
- NRXP 47.21
- Support Level
- CEV $9.37
- NRXP $2.40
- Resistance Level
- CEV $9.59
- NRXP $2.95
- Average True Range (ATR)
- CEV 0.07
- NRXP 0.22
- MACD
- CEV -0.01
- NRXP 0.02
- Stochastic Oscillator
- CEV 34.24
- NRXP 52.31
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.